Related Experiment Video
Updated: Nov 17, 2025

Zebrafish Model of Neuroblastoma Metastasis
Published on: March 14, 2021
GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma
Zhiwei Dong1, Kok Siong Yeo1, Gonzalo Lopez2
1Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota.
Abstract:
One of the greatest barriers to curative treatment of neuroblastoma is its frequent metastatic outgrowth prior to diagnosis, especially in cases driven by amplification of the MYCN oncogene. However, only a limited number of regulatory proteins that contribute to this complex MYCN-mediated process have been elucidated. Here we show that the growth arrest-specific 7 (GAS7) gene, located at chromosome band 17p13.1, is preferentially deleted in high-risk MYCN-driven neuroblastoma. GAS7 expression was also suppressed in MYCN-amplified neuroblastoma lacking 17p deletion. GAS7 deficiency led to accelerated metastasis in both zebrafish and mammalian models of neuroblastoma with overexpression or amplification of MYCN. Analysis of expression profiles and the ultrastructure of zebrafish neuroblastoma tumors with MYCN overexpression identified that GAS7 deficiency led to (i) downregulation of genes involved in cell-cell interaction, (ii) loss of contact among tumor cells as critical determinants of accelerated metastasis, and (iii) increased levels of MYCN protein. These results provide the first genetic evidence that GAS7 depletion is a critical early step in the cascade of events culminating in neuroblastoma metastasis in the context of MYCN overexpression. SIGNIFICANCE: Heterozygous deletion or MYCN-mediated repression of GAS7 in neuroblastoma releases an important brake on tumor cell dispersion and migration to distant sites, providing a novel mechanism underlying tumor metastasis in MYCN-driven neuroblastoma.See related commentary by Menard, p. 2815.
Insights
Growth arrest-specific 7 (GAS7) gene deletion or repression accelerates neuroblastoma metastasis. GAS7 deficiency in MYCN-driven tumors impairs cell-cell adhesion and increases MYCN protein levels, promoting tumor spread.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Neuroblastoma metastasis is a major challenge in curative treatment.
- MYCN oncogene amplification drives aggressive neuroblastoma.
- Limited understanding of regulatory proteins in MYCN-mediated metastasis.
Purpose of the Study:
- Investigate the role of the GAS7 gene in MYCN-driven neuroblastoma metastasis.
- Elucidate the mechanism by which GAS7 influences tumor cell behavior and spread.
Main Methods:
- Analysis of gene deletion and expression in neuroblastoma patient samples.
- Utilized zebrafish and mammalian models for in vivo studies.
- Examined gene expression profiles and tumor ultrastructure.
Main Results:
- GAS7 is preferentially deleted or downregulated in high-risk, MYCN-amplified neuroblastoma.
- GAS7 deficiency accelerates metastasis in preclinical models.
- GAS7 loss leads to reduced cell-cell adhesion and increased MYCN protein levels.
Conclusions:
- GAS7 acts as a tumor suppressor by inhibiting cell dispersion.
- GAS7 depletion is a critical early event in MYCN-driven neuroblastoma metastasis.
- Targeting GAS7 or its pathway may offer new therapeutic strategies.
More Related Videos
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...